本帖最后由 老马 于 2012-1-13 21:20 编辑
4 _/ m, l G; {( m3 J$ A) h7 N6 I6 }
爱必妥和阿瓦斯丁的比较2 }$ p6 O1 m8 W1 i7 w
- ?1 y( B7 q2 e3 m3 q% ^2 m. x
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/3 C) _+ b4 n( T
9 J; u# k6 ]0 l" N' L, ?
% l2 O3 G7 g: b1 W( w* w9 b/ o" Bhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
+ L# t0 W% i8 B- V# k==================================================
5 f+ v A# F; G6 k9 q y& O5 WOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)9 w' l2 q& J+ N$ J
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.% |7 M. f9 t3 s# p) @
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.6 k! H+ i) s3 _& z$ f6 f5 A
|